- Q3 2022 Nabriva Therapeutics PLC Earnings Call TranscriptNov 10, 2022$2.18 (+3.32%)Earnings
- Q2 2022 Nabriva Therapeutics PLC Earnings Call TranscriptAug 03, 2022$4.93 (+8.72%)Earnings
- Q1 2022 Nabriva Therapeutics PLC Earnings Call TranscriptMay 05, 2022$7.25 (-5.01%)Earnings
- Q4 2021 Nabriva Therapeutics PLC Earnings Call TranscriptMar 29, 2022$12.34 (+4.38%)Earnings
- Q3 2021 Nabriva Therapeutics PLC Earnings Call TranscriptNov 09, 2021$33.5 (+3.08%)Earnings
- Q2 2021 Nabriva Therapeutics PLC Earnings Call TranscriptAug 05, 2021$29 (-4.13%)Earnings
- Q1 2021 Nabriva Therapeutics PLC Earnings Call TranscriptMay 06, 2021$37.25 (-6.88%)Earnings
- Q4 2020 Nabriva Therapeutics PLC Earnings Call TranscriptMar 11, 2021$45.75 (+4.57%)Earnings
- Q3 2020 Nabriva Therapeutics PLC Earnings Call TranscriptNov 05, 2020$122.05 (+3.87%)Earnings
- Q2 2020 Nabriva Therapeutics PLC Earnings Call TranscriptAug 06, 2020$202.5 (-1.89%)Earnings
- Nabriva Therapeutics PLC at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 13, 2020
- Q1 2020 Nabriva Therapeutics PLC Earnings Call TranscriptMay 11, 2020$182.5 (+19.77%)Earnings
- Q4 2019 Nabriva Therapeutics PLC Earnings Call TranscriptMar 12, 2020$255 (-15.70%)Earnings
- Q3 2019 Nabriva Therapeutics PLC Earnings Call TranscriptNov 12, 2019$495 (-1.00%)Earnings
- Nabriva Therapeutics PLC at Morgan Stanley Healthcare Conference TranscriptSep 09, 2019
- Nabriva Therapeutics plc - Special Call TranscriptAug 19, 2019
- Nabriva Therapeutics PLC at Bank of America Merrill Lynch Health Care Conference TranscriptMay 15, 2019
- Nabriva Therapeutics plc Complete Response Letter from FDA on NDA Conference Call TranscriptMay 01, 2019
Nabriva Therapeutics plc Complete Response Letter from FDA on NDA Conference Call Transcript
Good day, ladies and gentlemen. Welcome to the Nabriva Therapeutics Conference Call. (Operator Instructions) As a reminder, this call is being recorded.
I would now like to introduce your host for today's conference, David Garrett, Vice President, Corporate Controller and Head of Investor Relations. Please go ahead.
Thank you, and good morning, everyone. Welcome to Nabriva's conference call to discuss the Complete Response Letter from the FDA for CONTEPO. A press release summarizing the Complete Response Letter was issued yesterday and can be found at www.nabriva.com.
Before we begin, I'd like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of the date of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)